Abstracts tagged "Biologic drugs"

Abstract Number: 1531 • 2015 ACR/ARHP Annual Meeting
The Changing Face of Septic Arthritis Complicating Rheumatoid Arthritis in the Era of Biotherapies. Retrospective Single-Center Study over 35 Years
Jean-Jacques Dubost¹, Bruno Pereira², Anne Tournadre³, Zuzana Tatar¹, Marion Couderc¹ and Martin Soubrier¹, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ³Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Rheumatoid arthritis (RA) is a risk factor for septic arthritis (SA), and anti-TNF therapy doubles the risk of SA. The purpose of this study…
Abstract Number: 1567 • 2015 ACR/ARHP Annual Meeting
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Matthew Wong-Pack¹, Rod Rodjanapiches¹, Arthur Lau^1,2,3, George Ioannidis^1,3, Sally Wade⁴, Leslie Spangler⁴, Celia JF Lin⁴, Patrick Roy-Gayos¹, William G Bensen^1,3, Robert Bensen³ and Jonathan D Adachi^1,3, ¹McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Previous studies combining immunosuppressive biologics have shown an increased risk of infections. Few studies have examined the risk of infection with concurrent use of…
Abstract Number: 430 • 2015 ACR/ARHP Annual Meeting
Adoption of Treat to Target Management in the Context of Achievable Goals and Satisfaction in RA
Peter C. Taylor¹, Juan J Gomez-Reino², Rieke Alten³, Philippe Bertin⁴, Roberto Caporali⁵, Emma Sullivan⁶, Robert Wood⁷, James Piercy⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ³Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁴Rheumatology, CHU Dupuytren, Limoges, France, ⁵University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁶Adelphi Real World, Manchester, United Kingdom, ⁷Adelphi Real World, Macclesfield, United Kingdom, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: The approach of setting disease activity targets and adjusting therapy appropriately to achieve the target has been proven to optimize outcomes in Rheumatoid Arthritis…
Abstract Number: 1980 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France
Alexis Regent¹, Serge Redeker², Alban Deroux³, Pierre Kieffer⁴, Kim Heang Ly⁵, Maxime Dougados⁶, Claire Larroche⁷, Loïc Guillevin¹, Laurence Bouillet⁸, Olivier Espitia⁹, Nathalie Costedoat-Chalumeau¹⁰, Martin Soubrier¹¹, Benoit Brihaye¹², François Lifermann¹³, Guillaume Lefèvre¹⁴, Xavier Puéchal¹, Luc Mouthon¹, Eric Toussirot¹⁵ and GFEV and CRI, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²43 rue de l'isle, Ch Abbeville, Abbeville, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Hopital Emile Muller, Mulhouse Cedex 1, France, ⁵CHU de Limoges, Service de médecine interne, Limoges, France, ⁶Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, ⁷Internal Medicine, Paris, France, ⁸CHU, Grenoble, France, ⁹Internal Medicine, Nantes University Hospital, Nantes, France, ¹⁰Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ¹¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ¹²Service de médecine interne et médecine polyvalente, Saint Quentin, France, ¹³CH Dax, Dax, France, ¹⁴Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁵Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose: To report the French experience on the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA) and outcome after treatment…
Abstract Number: 432 • 2015 ACR/ARHP Annual Meeting
Additional Intensive Treatment for Rheumatoid Arthritis Patients with Positive Power Doppler Signals Reduce the Radiological Joint Damage Even after Achieving Clinical Remission -SCRUM Study-
Tadashi Okano¹, Kentaro Inui², Masahiro Tada³, Yuko Sugioka⁴, Kenji Mamoto¹, Tatsuya Koike⁴ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopedic surgery, Osaka City General Hospital, Osaka, Japan, ⁴Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: The latest recommendations for the treatment of rheumatoid arthritis (RA) focus on the achievement of clinical remission. However, joints with subclinical positive power Doppler…
Abstract Number: 2059 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitor Tapering Induced Radiographic Progression Is Driven By Weighted Mean Disease Activity over Time, Not Flaring or Lower TNFi Exposition
Alfons A. den Broeder¹, Chantal A.M. Bouman¹, Aatke van der Maas², Frank H.J. van den Hoogen¹, Noortje van Herwaarden¹ and R. Landewe³, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Hengstdal 3, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, Netherlands
Background/Purpose: DRESS, a randomized controlled strategy trial (RCT)1investigating disease activity guided tapering of etanercept and adalimumab compared to usual care in RA patients, indicated that…
Abstract Number: 446 • 2015 ACR/ARHP Annual Meeting
Low Disease Activity at 12 Weeks and 24 Weeks Is Predictive of Normalized Health-Related Quality of Life in Methotrexate-Experienced Patients with Active Rheumatoid Arthritis Treated with Intravenous Golimumab Plus Methotrexate
Clifton O. Bingham III¹, Michael Weinblatt², Rene Westhovens³, Lilianne Kim⁴, Chenglong Han⁵, Stephen Xu⁴, Kim Hung Lo⁴, Kezhen L. Tang⁴, Elizabeth C. Hsia^4,6, Dennis Parenti⁷ and Shelly Kafka⁷, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³UZ Gasthuisberg, Leuven, Belgium, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Global Services, LLC, Malvern, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Previous analyses in patients (pts) with rheumatoid arthritis (RA) have evaluated the relationship between controlling disease activity and achieving long-term improvements in health-related quality…
Abstract Number: 2145 • 2015 ACR/ARHP Annual Meeting
Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, Philip J. Mease², Raquel S. Cuchacovich^3,4, Catherine L. Shuler⁵, Chen-Yen Lin⁵, Russel T. Burge⁵, Suvajit Samanta⁵, Chin H. Lee⁵ and Dafna D. Gladman⁶, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ³School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, ⁴Bio Medicines Business Unit/Autoimmune Medical, Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA has a significant negative impact…
Abstract Number: 464 • 2015 ACR/ARHP Annual Meeting
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
Cheryl Barnabe¹, Yufei Zheng², Arto Ohinmaa², Brenda Hemmelgarn³, Gilaad Kaplan⁴, Liam Martin⁵ and Walter Maksymowych⁶, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health Economics, Edmonton, AB, Canada, ³Division of Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Medicine, Medicine, University of Alberta, Edmonton, AB, Canada
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis Background/Purpose: Aboriginal people with rheumatoid arthritis (RA) have more severe disease and an…
Abstract Number: 2336 • 2015 ACR/ARHP Annual Meeting
Literature Review of Patient Reported Outcome and Health Related Quality of Life Measures for Biologic Therapies in the Management of Psoriatic Arthritis and Ankylosing Spondylitis
Steffen Jugl¹, Sultana Syeda² and Gunda Praveen², ¹BF I&D GPA, Health Economics and Outcomes Research, Novartis Pharma AG, Basel, Switzerland, ²Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India
Background/Purpose: Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic progressive conditions with substantial humanistic burden on patients and care givers. A variety of instruments,…
Abstract Number: 500 • 2015 ACR/ARHP Annual Meeting
Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis
Vidhu Anand¹, Sachit Anand², Sushil Garg³, Maria A. Lopez-Olivo⁴ and Jasvinder A. Singh⁵, ¹University of Minnesota, Minneapolis, MN, ²All India Institute of Medical Sciences, New Delhi, India, ³The University of Minnesota, Minneapolis, MN, ⁴General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ofatumumab is a unique anti-CD20 monoclonal antibody with its epitope more proximal and distinct from the epitope recognized by rituximab or by other anti-CD20…
Abstract Number: 2522 • 2015 ACR/ARHP Annual Meeting
High Risk of Flares during Pregnancy in Women with Rheumatoid Arthritis Who Discontinue Treatment with TNF Inhibitors at Conception
Rebecca Fischer-Betz¹, Oliver Sander¹, Christof Specker², Ralph Brinks³ and Matthias Schneider¹, ¹Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ²Rheumatology and clinical immunology, Kliniken Essen Sued, Essen, Germany, ³Hiller Center for Research in Rheumatology, Duesseldorf, Germany
Background/Purpose: Optimal treatment of women with Rheumatoid Arthritis (RA) during pregnancy remains a challenge, mainly due to safety concerns. TNF inhibitors (TNFi) are now routinely…
Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
KAZUYUKI YOSHIZAKI, Organic Fine Chemicals, The Institute of Scientific and Industrial Research, Osaka University, Suita, Japan
Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…
Abstract Number: 2557 • 2015 ACR/ARHP Annual Meeting
Comparable Therapeutic Potential of Umbilical Cord Mesenchymal Stem Cells in Collagen Induced Arthritis with Anti-Tumor Necrosis Factor or Anti-CD20
Yue Sun, Wei Kong, Weiwei Chen, Genhong Yao, Xuebing Feng and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Tremendous progress has been made in the development of non-conventional therapies for rheumatoid arthritis (RA). Mesenchymal stem cells (MSC) present multiple immunosuppressive capacities and…
Abstract Number: 517 • 2015 ACR/ARHP Annual Meeting
Investigating Psychological Predictors of Biologic Treatment Response in Patients with Severe Active Rheumatoid Arthritis
Bethan England¹, Lis Cordingley², Darren Plant³, Ann Morgan⁴, Anthony Wilson⁵, Kimme L. Hyrich⁶, Anne Barton⁷ and BRAGGSS Syndicate, ¹University of Manchester, Manchester, United Kingdom, ²School of Community Based Medicine, University of Manchester, Manchester, United Kingdom, ³arc Epidemiology Unit, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁵Genomic Medicine, The University of Sheffield, Sheffield, United Kingdom, ⁶Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Biologic therapy is now a cornerstone of RA management, but treatment response is variable, failing in up to 40% of patients. To direct appropriate…

« Previous Page
1
…
7
8
9
10
11
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].